Although these patients have extremely low NSP activity, they do not exhibit obvious immunodeficiency symptoms, providing important theoretical support for the safety of DPP1 inhibition therapeutic strategies (Pham et al., 2004). The gene discussed is CTSC; the disease is Immunodeficiency.